Lexaria Wins Strategically Important US Patent in Nicotine Space

Global innovator in drug delivery platforms, Lexaria Bioscience (Nasdaq: LEXX), has been granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office. The company’s share price rose nearly 20% following the news.

DehydraTECH-nicotine has shown in multiple animal studies that it can be delivered to the bloodstream up to 10-times to 20-times faster at up to 10-fold higher levels of nicotine into blood plasma from oral absorption than concentration matched controls.

Highlights

Lexaria’s new patent builds upon its growing patent portfolio in the oral nicotine delivery sector, including the white pouch category for both sublingual and buccal tissue delivery.

The oral nicotine pouch delivery method avoids harmful lung outcomes experienced by smokers or vapers, and involves buccal absorption of purified nicotine that has been separated from most other harmful compounds in the tobacco leaf.

Lexaria’s DehydraTECH-powered purified nicotine white pouch formulation contains no tobacco.DehydraTECH-nicotine is now patent granted for oral nicotine delivery in the U.S., Canada and Australia, and pending in numerous other countries.

The global market for the oral nicotine pouch category was $4.69 billion in 2022 and is expected to reach $11.91 billion in 2029.

About Lexaria Bioscience

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information, please visitwww.lexariabioscience.com.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Lexaria Wins Strategically Important US Patent in Nicotine Space

Editor Prism MarketView